Endocrine Abstracts

Diabetic gastroparesis (DG) is associated with high morbidity and is the most common precipitating factor to decompensation of carbohydrate metabolism. SGLT2 inhibitors are becoming a common and useful drug to treat type 2 diabetes. Principle treatment of gastroparesis considering the state of carbohydrate metabolism in patients with type 2 diabetes mellitus are very limited. The aim of this study was to compare the effects of dapagliflozin for management patients with DG. 16 patients with type 2 DM were randomly allocated into 2 groups: a first group (n=8 (3M/5F), mean age was 41.4±6.7 years old, DM during 12.2±5.4 years, body mass index (BMI) was 33.7±1.4 kg/m²) with gastroparesis, and a second (control) group (n=8 (4M/4F), mean age - 45.3±3.9 years old, DM - 13.2±6.2 years, BMI - 32.9±2.5 kg/m²) to take dapagliflozin (daily doses -10 mg) for 3 months. Gastric emptying rate (GER) measurement with the help ¹³C-octanoic breath test (¹³C-OBT), prandial and postprandial glucose levels and glycated haemoglobin (HbA₁C) were performed at entry and at end of treatment period as well. Low gastric motility has been diagnosed in all patients first group with help of ¹³C-OBT: T ½ - 98.84±4.22 min, in the second group that result is T ½ - 69.82±9.23 min. After the end of 3 months therapy in the first group significantly improved T ½ -83.11±2.31 min (P<0.05). In the result after treatment we show that glycemic control to be significantly higher (prandial glycemic-7.81±0.6 mmol/l, postprandial – 8.57±0.88 mmol/l, P < 0.05) in the patients of the first group than subjects of the second group (prandial glycemic- 8.44±0.34 mmol/l, postprandial – 9.28±0.13 mmol/l, P>0.05). After treatment level of HbA₁C significantly decrease in both groups (P<0.05).Dapagliflozin is an useful drug for treating type 2 diabetes with and without of gastroparesis. Patients with DG get normalization of gastric emptying rate. It appears that this effect may be due to non-specific mechanisms.